top of page
Grey Round Patterns
Sherringford's logo
You can find all our articles at portalnotes.app
We have moved to sherringford.org and portalnotes.app

Gilead Acquires Arcellx to Lead the Future of Multiple Myeloma Cell Therapy

Feb 24
2 min read
This image shows six executives, four men and two women, in a Gilead Sciences corporate meeting. Two of them shake hands over a glossy boardroom table in front of large city windows.

In a blockbuster move to revitalize its oncology pipeline, Gilead Sciences has announced a definitive agreement to acquire its longtime development partner, Arcellx, in a transaction valued at $7.8 billion.


Under the terms of the deal, which is expected to close in the second quarter of 2026, Gilead will pay $115 per share for the remaining stock of Arcellx it did not already own, representing a massive 79% premium. Arcellx stockholders could also receive an additional $5 per share contingent upon specific future sales milestones. Following the announcement, Arcellx shares skyrocketed by 78%, marking their best day on record.


The crown jewel of this acquisition is "anito-cel," an experimental multiple myeloma cell therapy currently under review by the Food and Drug Administration. The treatment modifies the body's immune T-cells to hunt and kill multiple myeloma, a progressive cancer of the bone marrow.

For Gilead, this $7.8 billion wager is a strategic necessity. The company's cell therapy business recently reported a 7% decline in overall sales and predicted a further 10% slide. Anito-cel could be the catalyst needed to turn this division around. Clinical trial results have shown a remarkable 96% response rate among patients whose cancer had relapsed or failed to respond to at least three prior treatments. Furthermore, Gilead anticipates that anito-cel will offer a better safety profile—specifically a lower risk of parkinsonism—compared to existing rival therapies from Johnson & Johnson and Bristol Myers Squibb.


Gilead’s CEO, Daniel O’Day, emphasized that anito-cel has the potential to become a "foundational treatment" for the disease, allowing the company to enter a highly lucrative $12 billion market for relapsed and refractory multiple myeloma.


This acquisition mirrors Gilead's $12 billion purchase of Kite Pharma nearly a decade ago, which established its initial foothold in cancer cell therapy. It also underscores a broader pharmaceutical industry trend of investing heavily in "living drugs," echoing Eli Lilly's recent $2.4 billion acquisition of the cell therapy biotech Orna Therapeutics.



🔖 Sources




Keywords: Multiple Myeloma Cell Therapy

Multiple Myeloma Cell Therapy



Sherringford logo

Comments

Rated 0 out of 5 stars.
No ratings yet

Add a rating

We designed Sherringford.org to be more than just an educational resource; it is a platform created to bring a fresh perspective to your daily professional life.

 

To achieve this ambitious goal, we decided to upgrade our site, and we invite you to visit our new space at

 

sherringford.org

​

We designed Sherringford.org to be more than just an educational resource; it is a platform created to bring a fresh perspective to your daily professional life.

 

To achieve this ambitious goal, we decided to upgrade our site, and we invite you to visit our new space at sherringford.org.

bottom of page